Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Using fibroblast growth factor to establish a line of embryonic stem cells

a technology of embryonic stem cells and growth factors, applied in the field of regenerative medicine, can solve the problems of considerably less advanced technology for culturing and differentiating human pluripotent stem cells, and achieve the effects of rapid production of high-quality pps cells, improving the quality and expansion rate of culture, and expanding primate pluripotent stem cells

Inactive Publication Date: 2005-07-14
ASTERIAS BIOTHERAPEUTICS INC
View PDF22 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014] This disclosure provides an improved system for expanding primate pluripotent stem (pPS) cells. The technology allows the user to rapidly produce high-quality pPS cells for use in therapy are drug discovery, free of undesired contamination by cells of other species and other tissue types.

Problems solved by technology

As a result, technology for culturing and differentiating human pluripotent stem cells is considerably less advanced.
A significant challenge to the use of pluripotent stem cells for therapy is that they are traditionally cultured on a layer of feeder cells to prevent differentiation (U.S. Pat. No. 5,843,780; U.S. Pat. No. 6,090,622).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Using fibroblast growth factor to establish a line of embryonic stem cells
  • Using fibroblast growth factor to establish a line of embryonic stem cells
  • Using fibroblast growth factor to establish a line of embryonic stem cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

Growing hES Cells Without Feeder Cells in Conditioned Medium

[0111] In this example, undifferentiated hES cells that had been maintained on primary mouse embryonic feeder cells were maintained in the absence of feeders. The culture wells were coated with Matrigel®, and the cells were cultured in the presence of conditioned nutrient medium obtained from a culture of irradiated primary fibroblasts.

[0112] Conditioned medium (CM) was prepared as follows. The fibroblasts were harvested from T150 flasks by washing once with Ca++ / Mg++ free PBS and incubating in trypsin / EDTA (Gibco). After the fibroblasts detached from the flask, they were collected in mEF medium (DMEM+10% FBS). The cells were irradiated at 4000 rad, counted and seeded at about 55,000 cells cm−2 in mEF medium. After at least 4 hours, the medium was exchanged with SR containing ES medium. Conditioned medium was collected daily for feeding of hES cultures. Alternatively, medium was prepared using mEF plated in culture flasks...

example 2

Phenotypic Markers of hES Cells in Feeder-Free Culture

[0120] Undifferentiated hES cells express SSEA-4, Tra-1-60, Tra-1-81, OCT-4, and hTERT. In order to assess whether the cells maintained in feeder-free conditions retained these markers, cells were evaluated by immunostaining, reverse transcriptase PCR amplification, and assay for telomerase activity.

[0121] For analysis by fluorescence-activated cell sorting (FACS), the hES cells were dissociated in 0.5 mM EDTA in PBS and resuspended to about 5×105 cells in 50 μL diluent containing 0.1% BSA in PBS. They were labeled with specific primary antibody and then fluorescent second antibody, and analyzed on a Flow Cytometer.

[0122] Similar to the hES cells on feeders, cells on Matrigel®, laminin, fibronectin or collagen IV expressed SSEA-4, Tra-1-60 and Tra-1-81. There was very little expression of SSEA-1, a glycolipid that is not expressed by undifferentiated hES cells.

[0123]FIG. 2 shows marker expression detected by immunocytochemist...

example 3

Pluripotency of hES Cells in Feeder-Free Culture

[0128] In vitro differentiation was induced in H1 hES cells maintained in conditioned medium on Matrigel®, laminin, fibronectin or collagen IV for 26 days. The hES cells were dissociated into small clumps by incubating in ˜200 U / mL collagenase IV at 37° C. for 10 min, and cultured in suspension to form embryoid bodies (EBs) in medium containing DMEM, 20% FBS (Hyclone), 1 mM glutamine, 0.1 mM-mercaptoethanol, and 1% non-essential amino acids (Gibco). After 4 days in suspension, the aggregates were transferred onto poly-ornithine-coated plates, and cultured for additional 7 days. The cultures were then examined for the presence of beating cells, and processed for immunocytochemistry.

[0129] The staining patterns were consistent with cells of the neuron and cardiomyocyte lineages (β-tubulin III and cardiac troponin 1, respectively). About 8 days after differentiation, beating regions were identified in all cultures. There were also cells...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
doubling timeaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

Description

REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09 / 859,291 (docket 091 / 006), filed May 16, 2001 (pending). [0002] This application is also a continuation-in-part of U.S. Ser. No. 10 / 330,873 (docket 061 / 006), filed Dec. 24, 2002 (pending); which is a divisional application of U.S. Ser. No. 09 / 530,346 (docket 061 / 005), filed Apr. 24, 2000 (now U.S. Pat. No. 6,800,480); which is the 35 USC § 371 U.S. National Stage of PCT application PCT / US98 / 22619, which was filed Oct. 23, 1998, and published as WO 99 / 20741 on Apr. 29, 1999. [0003] This application is also a continuation-in-part of U.S. Ser. No. 09 / 688,031 (docket 091 / 004), filed Oct. 10, 2000 (now U.S. Pat. No. 6,667,176); U.S. Ser. No. 09 / 849,022 (docket 091 / 005), filed May 4, 2001 (pending); U.S. Ser. No. 09 / 888,309 (docket 090 / 002), filed Jun. 21, 2001 (pending); and U.S. Ser. No. 09 / 900,752 (docket 092 / 002), filed Jul. 6, 2001 (now U.S. Pat. No. 6,642,048). [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/12C12N15/09A61P43/00C12N5/0735C12N5/077C12N5/079C12N5/0793C12N5/10C12N15/10
CPCC12N2501/237C12N5/0672C12N2502/99C12N2503/02C12N2506/02C12N2510/00C12N2510/04C12N2533/90C12N5/0606C12N5/0619C12N5/0622C12N15/1034C12N15/1096C12N2500/25C12N2501/115C12N2501/119C12N2501/125C12N2501/13C12N2501/145C12N2501/155C12N2501/2306C12N2501/235C12N2502/13C12N5/0678C12N11/04C12N2501/065C12N5/0603C12N2500/98C12N5/0693C12N5/0062C12N5/0662C12N5/0671C12N5/0075C12N5/0692C12N5/068C12N5/0607C12N2501/998C12N5/0068C12N2500/99C12N2501/105C12N2533/50C12N5/0696C12N2501/26C12N2500/90A61P43/00
Inventor MANDALAM, RAMKUMARXU, CHUNHUIGOLD, JOSEPH D.CARPENTER, MELISSA K.
Owner ASTERIAS BIOTHERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com